91 RESIST-TB. DR-TB Clinical Trial Progress Report. Date last accessed: 3 July 2023. www.resisttb.org/ clinical-trials-progress-report 92 Te Brake LHM, de Jager V, Narunsky K, et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg −1 rifampicin. Eur Respir J 2021 58: 2000955. 93 Velasquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. a randomized controlled trial. Am J Respir Crit Care Med 2018 198: 657–666. 94 Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 2017 17: 39–49. 95 Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015 191: 1058–1065. 96 Guglielmetti L, Gunther G, Leu C, et al. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J 2022 59: 2200388. 97 Masini T, Kanchar A, Mirzayev F, et al. Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally. Eur Respir J 2022 60: 2201227. 98 Nimmo C, Lipman M, Phillips PP, et al. Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. Lancet Infect Dis 2015 15: 141–143. 99 Phillips PP, Dooley KE, Gillespie SH, et al. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med 2016 14: 51. 100 Cellamare M, Ventz S, Baudin E, et al. A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials 2017 14: 17–28. 101 Cellamare M, Milstein M, Ventz S, et al. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis 2016 20: 8–12. 102 Horsburgh CR, Shea KM, Phillips P, et al. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials 2013 14: 88. 103 Quartagno M, Walker AS, Carpenter JR, et al. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clin Trials 2018 15: 477–488. 104 Guglielmetti L, Low M, McKenna L. Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking. Expert Rev Anti Infect Ther 2020 18: 701–704. 105 Lienhardt C, Vernon AA, Cavaleri M, et al. Development of new TB regimens: harmonizing trial design, product registration requirements, and public health guidance. PLoS Med 2019 16: e1002915. 106 Nyang’wa BT, LaHood AN, Mitnick CD, et al. TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 2021 22: 371. 107 Hills NK, Lyimo J, Nahid P, et al. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials 2021 22: 515. 108 Bonnett LJ, Ken-Dror G, Koh G, et al. Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early-phase clinical trials. Clin Infect Dis 2017 65: 46–54–. 109 Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 2022 400: 1858–1868-. 110 Guglielmetti L. Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Eur Respir J 2017 49: 1700738. Disclosures: C. Lange reports the following, outside the submitted work: receipt of consulting fees from INSMED receipt of speaker’s honoraria from INSMED and GILEAD membership of the data safety board of trails for MSF. L. Guglielmetti reports receiving grants or contracts from Unitaid, outside the submitted work. The remaining authors have nothing to disclose. 138 https://doi.org/10.1183/2312508X.10024622 ERS MONOGRAPH |THE CHALLENGE OF TB IN THE 21ST CENTURY